Seeking Alpha

Galena Biopharma, Inc. (GALE)

  • Jan. 13, 2014, 10:21 AM
    • Galena Biopharma (GALE +13.7%) rallies on news the company is buying Mills Pharmaceuticals, giving GALE rights to GALE-401 (CR anagrelide), a treatment for Essential Thrombocythemia.
    • In GALE's estimation, the drug "meets the qualifications for orphan drug status [and] has an estimated peak market size of approximately $200M in the U.S."
    • The company says a Phase 2 study should begin in "mid-2014."
    • GALE made an upfront payment to Mills' owners who are also eligible for stock grants and a milestone payment, the latter is contingent upon FDA approval of an NDA for '401. (PR)
    | Jan. 13, 2014, 10:21 AM | 5 Comments
GALE vs. ETF Alternatives
Company Description
Galena Biopharma Inc, is abiopharmaceutical company focused on developing and commercializing targeted oncology therapeutics that address medical needs across the full spectrum of cancer care.
Sector: Healthcare
Industry: Biotechnology
Country: United States